No Carolina / NY / Florida
Ph: 561.316.3330

No Carolina | NY | Florida

One Drop Improves Workplace Productivity for Older Adults with Type 2 Diabetes

Employees over 50 using One Drop saved time at work and improved on-the-job productivity, equating to over $13,000 in combined annual cost savings per person

Editor: What To Know

  • One Drop, a leader in precision health solutions for people living with diabetes and other chronic conditions, today announced analyses from a randomized control trial (RCT) on the impact of its award-winning digital health platform on workplace productivity (presenteeism) among people with type 2 diabetes published in the Journal of Occupational Environmental Medicine (JOEM).
  • The One Drop platform combines connected medical devices, an AI-powered mobile app (iOS and Android, available in 11 languages), and one-on-one coaching with certified diabetes care and education specialists (CDCES) to empower people with chronic conditions to stay healthy.
  • Most significantly, employees aged 50 and older using One Drop saved 8% of their time at work and 17% of on-the-job productivity, equating to $422 and $12,733 in average worker savings per year, respectively.

One Drop, a leader in precision health solutions for people living with diabetes and other chronic conditions, today announced analyses from a randomized control trial (RCT) on the impact of its award-winning digital health platform on workplace productivity (presenteeism) among people with type 2 diabetes published in the Journal of Occupational Environmental Medicine (JOEM). Employees using One Drop experienced significant productivity and functioning gains and were less likely to experience presenteeism at follow-up compared to control groups.

Six in 10 Americans live with at least one chronic condition, and many go to work—virtually or in person—regardless of acute illness or nagging symptoms. Known as presenteeism, working at minimal capacity due to health problems correlates to a 33% average reduction in individual productivity and $1,500 billion in related employer costs. While few randomized controlled trials have shown mHealth applications for condition management to affect workplace productivity (presenteeism), the present study indicates the One Drop platform is an economical solution yielding substantial benefits for adults with type 2 diabetes. Most significantly, employees aged 50 and older using One Drop saved 8% of their time at work and 17% of on-the-job productivity, equating to $422 and $12,733 in average worker savings per year, respectively.

“A healthy and productive workforce is critical for economic success and population health. Leaders who recognize this vital connection are investing in technology, like One Drop, that helps people function better day-to-day at work—where the average employee spends a third of their life”, said Jeff Dachis, CEO and founder of One Drop. “When combined with established clinical, psychological, and behavioral outcomes, productivity gains paint a complete picture of how our predictive health platform positively impacts all aspects of someone’s life—at home, at work, and beyond.”

The One Drop platform combines connected medical devices, an AI-powered mobile app (iOS and Android, available in 11 languages), and one-on-one coaching with certified diabetes care and education specialists (CDCES) to empower people with chronic conditions to stay healthy. More than 20 peer-reviewed clinical studies demonstrate One Drop’s results and clinical strengths, including improved health outcomes (e.g., 1.9% reduction in estimated A1C in three months, lower systolic blood pressure, average nine-pound weight loss) and direct per-person annual cost savings. The latest RCT results suggest One Drop may also enable better day-to-day functioning for adults managing diabetes. Possible reasons include reduction of treatment-related burnout, removal of health-related stress or distractions, and increased concentration and energy.

To date, One Drop has aggregated more than 42 billion longitudinal health data points from approximately 1.5 million installed members worldwide. The precision health company uses this wealth of data to train the proprietary machine learning algorithms behind its predictive features, including CE-marked eight-hour glucose forecasts—now linked to improved engagement and diabetes outcomes.

One Drop is currently developing a minimally invasive health sensor with continuous glucose monitoring (CGM) capabilities designed to provide greater flexibility and insights for people with diabetes compared to blood glucose monitoring (BGM) fingersticks alone. Pending regulatory approval and commercial adoption, One Drop believes that integrating its proprietary sensor and existing digital solution should augment proven outcomes and yearly cost savings for members with diabetes and other chronic conditions. The availability of this device is subject to receipt of clearance or approval from the U.S. Food and Drug Administration.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Recent News

CV Societies Propel Plans Forward for a New Board of Cardiovascular Medicine

“The open comment period is the time for cardiovascular physicians, allies in other medical specialties, patients, and others to make their voices heard on why an independent CV Board is the best path for cardiologists to stay up-to-date on best practices and evidence-based care, ensuring patients receive the best possible care,” said Jeffrey Kuvin, MD, president of the proposed Board’s new Board of Directors. “The field of cardiovascular medicine has evolved dramatically over the past few decades; now is the right time to develop an independent cardiovascular Board.”

Hyundai Bioscience Announces Clinical Development Plan for Niclosamide-based Metabolic Anticancer Drug Targeting P53 Mutation Cancer

Sang-ki Oh, CEO of Hyundai Bioscience, stated, "Niclosamide-based metabolic anticancer drug candidate will be the first P53-targeting anticancer treatment that selectively kills p53 mutated cancer cells," and added, "Through our subsidiary ADM Korea, we plan to conduct clinical trials targeting cancer patients with intractable cancer caused by p53 mutations, which will be the first step of clinical development on niclosamide-based anticancer agent pipeline."

Sedana Medical Completes Patient Recruitment for INSPiRE-ICU 1 Clinical Trial in the US

Peter Sackey further elaborated: "Once the 30-day follow-up of all patients is complete, we will enter into an intense phase of final monitoring, data cleaning and transfer to our statistician team for analysis. In parallel, the long-term outcomes at 3 and 6 months will be collected centrally by the Critical Illness, Brain Dysfunction, and Survivorship team at Vanderbilt Medical Center. With this parallel approach, we expect topline results in the autumn of this year and a swift regulatory submission in Q1, 2025".

Health / Lifestyle

Articles of Interest

Stay Connected

spot_img

About Medical Device News Magazine

About Medical Device News Magazine. A digital publication founded in 2008 located in the United States. The publication is one of the industry’s leading sources of medical device and biotech industry updates. Medical Device News Magazine is easily accessible 24/7/365 and is a fast 1, 2, 3 easy read! Our purpose is...

By using this website you agree to accept Medical Device News Magazine Privacy Policy